Martin Bögemann
University Hospital Münster(DE)
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Radiopharmaceutical Chemistry and Applications, Bladder and Urothelial Cancer Treatments, Prostate Cancer Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → German Multicenter Study Investigating177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients(2016)816 cited
- → Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial(2020)489 cited
- → Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study(2015)293 cited
- → Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1(2016)244 cited
- → Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial(2023)200 cited
- → Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer(2016)184 cited
- → 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer(2017)173 cited
- → Correlation of Intraprostatic Tumor Extent with 68Ga-PSMA Distribution in Patients with Prostate Cancer(2016)150 cited
- → Targeting PSMA by radioligands in non-prostate disease—current status and future perspectives(2018)141 cited
- → Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)(2020)126 cited